tility of Hydroxychloroquine medicine as a supportive treatment for breast cancer patients

Phase 4

• Conditions: Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

• Registration Number: CTRI/2023/11/059909
• Lead Sponsor: Dr Ananth Pai

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 19 December 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients diagnosed with triple negative breast cancer and receiving neoadjuvant chemotherapy (NACT).

Age more than 18yrs

Performance Status less than or equal to 2

Exclusion Criteria

•Metastatic triple negative breast cancer.

•Patients taking alternative therapies concurrently.

•Receipt of hydroxychloroquine (HCQ) within the past 6 months.

•History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Demographiccharacteristics,clinicalpresentations, histopathologyreports, diagnostic results, and treatment details. <br/ ><br>2.Genomic and proteomic analysis will be carried out. <br/ ><br>3.Change in Prostate Apoptosis Response-4 (PAR-4) Levels. <br/ ><br>4.PAR-4 levels measured via serum or plasma blood sample. <br/ ><br>Timepoint: 0 weeks, 2 weeks and at the end of treatment

Secondary Outcome Measures

Name	Time	Method
nilTimepoint: nil